All News
This is how Dr. Berstein manages SSc-ILD #ACR22 @rheumnow #CurbsideConsult https://t.co/vP7m0WpdK6
TheDaoIndex KDAO2011 ( View Tweet)
Abdel-Wahab et al. TCZ in combo with ipilimumab/nivolumab. Very preliminary results of what will be important trial. Appears safe and well-tolerated with no increased risk cancer progression. @RheumNow #ACR22 Abstr#1670 https://t.co/uPBnHJ9BRH
Richard Conway RichardPAConway ( View Tweet)
Messier et al. WE-CAN pragmatic trial of diet and exercise (vs attention control) in knee OA with high BMI. Significant improvement in pain, walk distance, SF-36 with corresponding reduction in body weight @RheumNow #ACR22 Abstr#1675 https://t.co/uSSzx4u2sp https://t.co/upnIVecRjv
Richard Conway RichardPAConway ( View Tweet)
SAPHYR results: SAR + 14 wk GC taper showed efficacy vs comparator arm in steroid refractory PMR, including clinically meaningful improvement in QoL. No new safety signals. Plenary Abs 1676 #ACR22 @RheumNow https://t.co/mHu3e9JbCp https://t.co/93kbczSTfS
Dr. Rachel Tate uptoTate ( View Tweet)
Tonight at 7pm ET! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan
@RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan #ACR22
https://t.co/hIH4WghLwN https://t.co/oKQbBnMiqQ
Links:
Dr. John Cush RheumNow ( View Tweet)
This slide reminds me of a recent case I encountered 🧐
How can we differentiate #vasculitis vs. atherosclerosis? 👇
TAK - stenosis occurs in proximal arteries, thoracic aneurysms, US: conc, smooth thickg w/ long segment stenosis
#ACR22 @Rheumnow #RheumTwitter @rheumarhyme https://t.co/So4VKsfBm4
sheila RHEUMarampa ( View Tweet)
In overweight and obese patients with knee OA, 18-months of diet and exercise delivered in community settings significantly reduced WOMAC knee pain (-0.6) compared to an attention control group. Messier S Abs#1675 https://t.co/GvPCGz0NMN #ACR22 @RheumNow https://t.co/yWAwGwunzT
Dr. Antoni Chan synovialjoints ( View Tweet)
Ab1672 #ACR22 SSc on Women's Health
100 pts - 75% lSSc
59% sexuality aff by SSc (vag dryness 67%, dig ulcers 37%, GI 37%, dyspnea 20%)
48 pts dx during repro ys - 73% never discuss contraception, 30% didn't reach family plan
22 pt - 43 pregn, 33 birth: C-sxn, low bth wt
@Rheumnow https://t.co/JRkyCVEXLB
Eric Dein ericdeinmd ( View Tweet)
More than 25,000 #ACR22 tweets since November 1 - keep going strong today and we will reach 100,000,000 impressions. Congrats to @rheum_cat, @RheumNow and @CreakyJoints for having the most impact with over 10M impressions each. @ACRheum @StevenEchard https://t.co/K2Kr4sAicS
Steven Echard, CAE StevenEchard ( View Tweet)
Sometimes your RA pts are eligible for ICI cancer immunotherapy, but there’s hesitancy because of autoimmune risk/bad irAEs
@DanaFarber @MassGenBrigham:
more RA flares
but similar mortality, severe irAEs rates
Give them what they need!
ABST1667 @jeffsparks #ACR22 @RheumNow https://t.co/WdDP8IeIYG
David Liew drdavidliew ( View Tweet)
Sarilumab (SAR) + 14 wk GC taper demonstrated significant efficacy vs the comparator arm in steroid refractory PMR patients and improvement in quality of life. Sustained remission was 28.3% SAR vs 10.3% comparator arm. Spiera R Abs#1676 https://t.co/gXGJzbYLHK #ACR22 @RheumNow https://t.co/oZBsRtxMUw
Dr. Antoni Chan synovialjoints ( View Tweet)
Very interesting Thieves Market case... which I have also seen!
Don't forget mycoplasma pneumoniae-induced rash and mucositis (MIRM) when patients presen tw/oral ulceration
My patient had +ANA and carried a dx of PFAPA; only responded to abx!
#ACR22 @RheumNow ABSTR#TMO2 https://t.co/B9dBkZyrlN
Mike Putman EBRheum ( View Tweet)
What's your view look like? Are you in-person or virtual? Share a picture from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/DE7HhDzyJY
Dr. John Cush RheumNow ( View Tweet)
#abst1679 #acr22 @rheumnow CARRA STOP-JIA early introduction of bDMARD beneficial in polyarticular JIA: in early combination of cDMARD+biologic group > pts able to achieve Clinical Remission& significantly longer T spent in CID& cJADAS10 ID during the 3 year study vs step up Rx https://t.co/xwQJnSeCNE
Olga Petryna DrPetryna ( View Tweet)
Promising data on denosumab in erosive OA
Phase 2 study - less erosive progression, more symptom improvement
Abs# L05 @RheumNow #ACR22 https://t.co/9Fg3r02ZQG
Robert B Chao, MD doctorRBC ( View Tweet)
Wittoek et al. 48-week RCT of Denosumab in erosive hand OA. Prevents structural progression! @RheumNow #ACR22 Abstr#L05 #ACRbest https://t.co/CI6VBERSmn https://t.co/OszJkGeJF7
Richard Conway RichardPAConway ( View Tweet)
L05 #ACR22 High-dose Denosumab in Erosive Hand OA
48Wk, Double-blind PBO Phase 2 100 patients
GUSS change higher in DEN v PBO at w24, incr at w48
New erosions lower in DEN w48 (2% v 7%, OR 0.23, p<0.001)
Open label extension w improvement to baseline
@RheumNow https://t.co/X6MF9q2bKj
Eric Dein ericdeinmd ( View Tweet)
This single ctr retrospective cohort study by AOhayn on antiRo/La+ moms show that the mean timing of first fetal echo for CHB screening was at 20wks AOG.
💠CHB+ in 3 fetuses on 1st echo (done 19, 22.4, 29.3 wks)
Take home msg? Do timely CHB screens
#ACR22 @RheumNow ABST#0957 https://t.co/59crW0uov4
sheila RHEUMarampa ( View Tweet)
Walrabenstein et al. RCT of 16-week triple intervention - plant-based diet, exercise, stress management - vs usual care in OA. It works, but we don't know which component, or if Hawthorn effect @RheumNow #ACR22 Abstr#1644 https://t.co/p74Ptd8bZ2 https://t.co/EOg7RxRmO7
Richard Conway RichardPAConway ( View Tweet)
Maya Buch on major adverse CV events in tofa vs TNFi. Post-hoc analysis of phase 3b/4 data looking at cohort enriched for CV events.
@RheumNow #ACR22 #LateBreaking
Julian Segan JulianSegan ( View Tweet)